Pharma Two B – Developing Innovative Pharmaceutical Products

About Us
Why P2B001
About PD
News & Events
- Press Releases
- Events
Contact Us

About Us
Why P2B001
About PD
News & Events
- Press Releases
- Events
Contact Us

Optimizing

the treatment of Parkinson’s disease

Improved

* As demonstrated in Phase III clinical study motor symptoms and daily function*

Good tolerability

* As demonstrated in Phase III clinical study and safety*

Once-daily capsule

no need for titration

P2B001 Completed

Phase 3 Study in Early PD

OUR COMPANY

We are striving to improve patients’ quality of life by developing innovative combination products, based on previously approved drugs, with favorable balance between safety and efficacy.

WHAT IS P2B001?

P2B001 is a novel, once-daily combination of extended-release (ER) pramipexole, a low dose dopamine agonist (0.6mg), and rasagiline, a low dose MAO-B inhibitor (0.75mg), developed specifically for the treatment of..

LATEST NEWS

Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson’s Disease and Movement Disorders®

September 15, 2022

Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting

April 5, 2022

Advances in Therapy publishes Pharma Two B’s review paper, “P2B001 (extended release pramipexole and rasagiline): A new treatment option in development for Parkinson’s disease”

March 14, 2022

OUR MISSION

We are striving to improve patients’ quality of life by developing innovative combination products, based on previously approved drugs,
with favorable balance between safety and efficacy.